Real-world clinical effectiveness and safety of vedolizumab and ustekinumab in biologic-naive patients with Crohn's disease: Results from the EVOLVE Expansion study

被引：0
|
作者：
Ferrante, M. [1 ]
Christensen, B. [2 ,3 ]
Bressler, B. [4 ]
Brett, N. [5 ]
Bassel, M. [5 ]
Kamble, P. [6 ]
Adsul, S. [6 ]
Gianchetti, L. [7 ]
Scharl, M. [8 ]
机构：
[1] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Gastroenterol & Hepatol, Leuven, Belgium
[2] Royal Melbourne Hosp, Dept Gastroenterol, Melbourne, Vic, Australia
[3] Univ Melbourne, Dept Med, Melbourne, Vic, Australia
[4] St Pauls Hosp, Vancouver, BC, Canada
[5] Thermo Fisher Sci, PPD, Montreal, PQ, Canada
[6] Takeda Pharmaceut, Cambridge, MA USA
[7] Thermo Fisher Sci, PPD, Philadelphia, PA USA
[8] Univ Zurich, Univ Zurich Hosp, Dept Gastroenterol & Hepatol, Zurich, Switzerland
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2023年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
26
引用
收藏
页码：116 / 117
页数：2
相关论文
共 50 条
  • [31] Vedolizumab outcomes in real-world bio-naive ulcerative colitis and Crohn's disease patients (EVOLVE) in Canada: Interim results
    Bressler, B.
    Greenup, A. -J.
    Bassel, M.
    Stein, D.
    Soni, M.
    Radulescu, G.
    Neish, C.
    Khalid, J. M.
    Demuth, D.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S382 - S382
  • [32] REAL-WORLD EFFECTIVENESS OF FIRST-LINE BIOLOGIC VEDOLIZUMAB IN CROHN'S DISEASE: ANALYSIS OF HIGHER TREATMENT EFFECT SUBPOPULATION FROM THE EVOLVE STUDY
    Yarur, Andres
    Bressler, Brian
    Wang, Song
    Adsul, Shashi
    Kamble, Pravin
    Luo, Michelle
    Cook, Erin
    Sajeev, Gautam
    Dieye, Ibou
    Mantzaris, Gerassimos J.
    GASTROENTEROLOGY, 2021, 160 (06) : S4 - S4
  • [33] Comparison of Surgery Rates in Biologic-Naive Patients With Crohn's Disease Who Were Treated With Vedolizumab or Ustekinumab: Findings From SOJOURN
    Vu, Michelle
    Ghosh, Sabyasachi
    Umashankar, Kandavadivu
    Chastek, Benjamin
    Candela, Ninfa
    Weber, Laura A.
    Landis, Christina
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S715 - S716
  • [34] Comparison of Surgical Rates in Biologic Naive Crohn's Disease Patients on Ustekinumab and Vedolizumab
    Mohammed, Abdul
    Alchirazi, Khaled Alsabbagh
    Hamid, Osama
    Eltelbany, Ahmed
    Garg, Rajat
    Paranji, Neethi
    Gonzaga, Ernesto Robalino
    Singh, Amandeep
    Kais, Susan
    Regueiro, Miguel
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S706 - S707
  • [35] PATIENTS WITH CROHN'S DISEASE TREATED WITH USTEKINUMAB VERSUS VEDOLIZUMAB IN REAL-WORLD SETTINGS
    Chiorean, Michael V.
    Jiang, Jeanne
    Candela, Ninfa
    Chen, Grace
    Romdhani, Hela
    Latremouille-Viau, Dominick
    Shi, Sherry
    Bungay, Rebecca
    Fan, Tao
    GASTROENTEROLOGY, 2020, 158 (06) : S407 - S408
  • [36] Real-world effectiveness and safety of ustekinumab for the treatment of Crohn's disease: the Scottish ustekinumab cohort
    Plevris, Nikolas
    Fulforth, James
    Siakavellas, Spyros
    Robertson, Andrew
    Hall, Rebecca
    Tyler, Amy
    Jenkinson, Philip W.
    Campbell, Iona
    Chuah, Cher Shiong
    Kane, Claire
    Veryan, Jennifer
    Lam, Wai Liam
    Saunders, Jayne
    Kelly, Christopher
    Gaya, Daniel
    Jafferbhoy, Hasnain
    Macdonald, Jonathan C.
    Seenan, John Paul
    Mowat, Craig
    Naismith, Graham
    Potts, Lindsay F.
    Sutherland, Diarmid Ian
    Watts, David
    Arnott, Ian
    Bain, Gillian
    Jones, Gareth
    Lees, Charlie W.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 (08) : 2067 - 2075
  • [37] Safety and Effectiveness of Ustekinumab for Crohn's Disease in Japanese Post-marketing Surveillance in Biologic-Naive and -Experienced Conriemed
    Nagano, Katsumasa
    Hata, Erina
    Asano, Teita
    Tsuchiya, Hiroaki
    Takagishi, Masayuki
    Yamazaki, Hiroshi
    Tominaga, Sonoko
    Matsumoto, Takayuki
    CROHNS & COLITIS 360, 2023, 5 (01)
  • [38] Clinical effectiveness and safety of first-line biologic vedolizumab as a monotherapy or combination therapy in ulcerative colitis and Crohn's disease patients: results from the EVOLVE study
    Bressler, B.
    Yarur, A.
    Kopylov, U.
    Bassel, M.
    Brett, N.
    Colby, C.
    Lopez, C.
    Saha, S.
    Kifnidi, C.
    Agboton, C.
    Adsul, S.
    Demuth, D.
    Luo, M.
    Wang, S.
    Mantzaris, G. J.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S381 - S382
  • [39] CLINICAL EFFECTIVENESS AND SAFETY OF FIRST-LINE BIOLOGIC VEDOLIZUMAB AS A MONOTHERAPY OR COMBINATION THERAPY IN ULCERATIVE COLITIS AND CROHN'S DISEASE PATIENTS: RESULTS FROM THE EVOLVE STUDY
    Bressler, Brian
    Yarur, Andres J.
    Kopylov, Uri
    Bassel, Marielle
    Brett, Neil R.
    Colby, Chris
    Lopez, Claudia
    Saha, Sumit
    Kifnidi, Christina
    Agboton, Christian
    Adsul, Shashi
    Demuth, Dirk
    Luo, Michelle
    Wang, Song
    Mantzaris, Gerassimos J.
    GASTROENTEROLOGY, 2020, 158 (06) : S407 - S407
  • [40] Effectiveness and Safety of ustekinumab in the Treatment of Penetrating Crohn's Disease: A Prospective Real-World Study
    Wu, Y.
    Huang, Z.
    Deng, X.
    Chao, K.
    Wu, Yan-Hui
    Huang, Zhao-Peng
    Deng, Xiao-Xia
    Lin, Min-Zhi
    Huang, Zi-Cheng
    Gao, Xiang
    Chao, Kang
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1413 - i1414
12345